Lupus & antiphospholipid syndrome
Anti-TFAM antibodies link mitochondrial damage with antiphospholipid syndrome and thrombosis in systemic lupus erythematosus (SLE)
Authors' conclusion
Anti-TFAM antibodies identify a distinct clinical and transcriptional disease subset associated with mitochondrial damage, thrombosis, and APS in SLE.
Study context
- Population
- Patients with SLE and healthy controls; sera from dermatomyositis, RA and primary antiphospholipid syndrome (APS) (primary antiphospholipid syndrome (PAPS)) also testedexploratory sample 22 SLE, 9 controls
- Participants
- 158 vs 98
- Exposure
- Anti-TFAM-positive vs anti-TFAM-negative SLE patients
- SLEn = 158
- Healthy controlsn = 98reference
- Outcome
- Prevalence and clinical significance of anti-TFAM antibodies, and associations with transcriptional profiles and IFN levels
Methodological detailsexploratory discovery sample, enzyme-linked immunosorbent assay (ELISA) validation cohort
- Exploratory discovery sample
- ELISA validation cohort
Main finding
As reported in the abstract
Anti-TFAM antibody positivity in SLE
SLE
One-third
48 of 158
Observational data: associations, not effects.
Further findings
Thrombosis associated with anti-TFAM antibodies
- OR for thrombosis with anti-TFAM antibodies
- 2.9
APS associated with anti-TFAM antibodies
- OR for APS with anti-TFAM antibodies
- 5.4
Thrombosis with anti-TFAM antibodies plus LA
- OR for thrombosis with anti-TFAM antibodies when LA present
- 8.71
- LA increased the risk of thrombosis associated with anti-TFAM antibodies
Disease activity and IFN signature
- Anti-TFAM antibodies not associated with disease activity or the IFN signature
Original publication
Anti-TFAM antibodies link mitochondrial damage with antiphospholipid syndrome and thrombosis in SLE. Ann Rheum Dis. Published 10 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →